Viatris has been on a strong run, and with the stock recently closing at US$19.91 after a period of solid gains, the key question is whether that price still lines up with the sales the business is generating. For a company that is also pursuing acquisitions and product approvals, you need to ask how much of that story is already reflected in the revenue multiple.
-
Over the past 3 years Viatris has delivered a 145.5% share price return, which puts real weight on whether investors are paying a stretched or still reasonable price relative to its sales base.
-
The planned US$1.65b purchase of Pacira BioSciences can reshape Viatris' mix of promoted brands and non opioid pain treatments, which may influence how investors think about future revenue scale and the sales multiple they are prepared to pay today.
-
The analysts covering Viatris have run their own numbers. See what analysts think Viatris's shares could be worth .
The issue now is whether the current Viatris share price is justified by its sales when set against the Fair Ratio benchmark.
If you are weighing whether Viatris' current P/S still feels reasonable after a 145.5% three year run, it can help to compare it with 39 high quality undervalued stocks .
Is Viatris a Bargain on Sales?
The P/S ratio fits Viatris because revenue tends to be more stable than earnings for a pharmaceutical group investing heavily in products and deals. At a P/S of 1.5x, the stock trades well below the Pharmaceuticals industry average of 4.2x and the peer group at 5.1x, so each dollar of Viatris sales is priced at a clear discount to many rivals.
On Simply Wall St's Fair Ratio framework, which adjusts the P/S you might expect for Viatris based on its size, margins, sector and risk profile, the current multiple also sits below the level implied by those fundamentals. Because the Pacira BioSciences tender offer and recent product approvals have already raised expectations, this gap suggests the market still prices Viatris more cautiously than both that tailored benchmark and typical sector valuations. Explore the numbers behind Viatris's P/S valuation .
The Viatris Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Viatris valuation question leaves off by spelling out what kind of future for growth, margins and earnings would have to play out for the shares to look meaningfully cheaper or more expensive than they do today on the current P/S. Each one sets out Viatris' implied worth as a concrete thesis about the business so you can see how the underlying argument holds up over time, and they sit on Simply Wall St's Community page.
Bulls see Viatris as a cleaner, higher value portfolio in the making, while bears focus on whether execution can really keep up with those expectations.
Bull case: roughly fairly valued
"Expansion of higher-value branded and complex products such as the Gwyn Lo contraceptive patch and the planned Creon dose escalation label update in Europe is expected to shift Viatris' mix away from lower-margin oral generics and support revenue growth and gross margin resilience..."
Discover why this Narrative puts Viatris at roughly fairly valued .
Bear case: 42% overvalued
"The numbers currently reflected in the share price imply that Viatris shares already discount a successful transition toward value-added medicines, continued growth in regions such as Greater China and sustained capital returns, which leaves limited room for disappointment if execution slips..."
Explore why this Narrative puts Viatris at 42% overvalued .
Viatris' price tag is only one piece of the decision
Before you lean too heavily on the current P/S and the narrative around Pacira BioSciences, it is worth checking the specific risk flags our research has picked up on Viatris. Take a closer look at 1 warning sign before settling on a valuation.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include VTRS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
